Introduction
Renal fibrosis, characterized by tubulointerstitial fibrosis and glomerulosclerosis, is the final manifestation of chronic kidney disease (CKD) 1) . The progression of CKD, one of the biggest problems in nephrology, indicates that patients inevitably reach endstage renal disease (ESRD) and require renal replacement therapies such as dialysis and transplantation 2) . Although a range of diseases such as glomerulonephritis; metabolic diseases, including diabetes mellitus and atherosclerosis; obstructive nephropathy; interstitial nephritis; and cystic nephropathies, including polycystic kidney disease, can be the major causes of CKD, renal fibrosis is always the common ultimate result of CKD 3, 4) . Renal fibrosis is characterized by an excessive accumulation and deposition of extracellular matrix (ECM) components 1) . In order to elucidate the specific pathway of renal fibrosis, many experimental studies have been conducted using laboratory animals [5] [6] [7] [8] [9] [10] [11] [12] . This review article will focus on recent advances in the pathogenesis of renal fibrosis and review the therapeutic trials conducted with an aim to overcome renal fibrosis.
Experimental models of renal fibrosis
Most of the present knowledge about the pathogenesis of renal fibrosis is based on experimental studies with laboratory animals. However, only few studies have reported the common features of renal fibrogenesis, such as interstitial fibrosis, tubular atrophy, and glomerulosclerosis 5) . Nephrotoxic serum nephritis (NSN) is a frequently used model for anti-glomerular basement membrane (anti-GBM) disease or in situ immune-complex glomerulonephritis and is characterized by an early heterologous phase, including linear deposition of anti-GBM antibody in the glomerulus and a subsequent autologous immune response against the planted antibodies 6) . NSN has been effectively used as a model for fibrosis with CD-1 mice, C57BL/6 mice, and various gene-knockout mice 5) . Fibrotic lesions, including collagen deposition in the interstitium, increased fibroblasts, epithelial-to-mesenchymal transition (EMT), appear after 1-2 weeks of NSN and severe tubulointerstitial fibrosis is noted between 3 and 6 weeks 5) .
Mice with an intended disruption of the COL4A3 gene, which
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encodes the α3 chain of type IV collagen, were initially generated as a model for Alport syndrome 7, 8) . In this animal model, the primary renal pathologic finding is the splitting of the GBM and subsequent crescentic glomerulonephritis and renal fibrosis 7, 9) . Unilateral ureteral obstruction (UUO), as a model similar to human obstructive nephropathy, is induced by the ligation of a ureter of one kidney, while the contralateral kidney serves as a control; at as early as 3 days after UUO surgery, interstitial fibrosis associated with interstitial deposition of type IV collagen and tubular cell apoptosis are noted 10) . Thornhill et al. 13) reported that tubular atrophy and interstitial fibrosis develop before significant renal pelvic dilatation in a neonatal rat model with variable chronic partial UUO, and that renal growth is reduced by 60% after 70% reduction of ureteral diameter. Moreover, although UUO is relieved after brief periods of obstruction, recovery from either structural or functional damages due to obstructive uropathy cannot be always guaranteed 14) . In the murine model of Denys-Drash syndrome, mice strains generated by crossbreeding of Wilms' tumor 1 gene (WT-1) knockout mice and mice with a yeast artificial chromosome containing the WT-1 locus can present with either crescentic glomerulonephritis or mesangial sclerosis depending on the relative WT-1 expression levels 11) . Assmann et al. 12) reported that transgenic mice with ectopic expression of the Thy-1.1 antigen on the podocyte gradually and spontaneously develop focal glomerulosclerosis.
Pathogenesis and therapeutic trials of renal fibrosis
Renal fibrosis is characterized by glomerulosclerosis, tubulointerstitial fibrosis, loss of renal parenchyme, and inflammatory cell infiltration 1) (Fig. 1A, 1B ). These pathologic results usually originate from the underlying complicated cellular conditions such as the activation of EMT and fibroblasts, monocyte/macrophage infiltration, and cellular apoptosis 1, 15) . An early renal insult can evoke the activation of tubular cells that leads to the production of proinflammatory molecules that eventually contribute to renal fibrosis 15) . If high-grade proteinuria in tubular area develops due to the injured glomerular barrier, tubular cells can be exposed to bioactive molecules in the plasma or inflamed glomeruli 16) , thereby leading to the production of various chemotactic cytokines such as monocyte chemoattractant protein-1 (MCP-1) 17, 18) ; regulated upon activation, normal T cell expressed and secreted (RANTES) 19) ; and potent monocyte chemoattractants such as C3a and C5a 20, 21) . Moreover, leukocyte adhesion molecules such as osteopontin, intercellular adhesion molecules (ICAMs), and vascular cell adhesion molecules (VCAMs) have been reported to originate from tubules and to play an essential role in mononuclear cell recruitment in chronic renal disease state 22, 23) . Due to the activation of these various chemokines and chemoattractants, most of monocytes move into the glomerular and interstitial area from the circulation via peritubular capillary epithelium and infiltrated monocytes, leading to the production of inflammatory and fibrogenic cytokines, as well as injurious molecules, including reactive oxygen species (ROS) 1) . Finally, these inflammatory stimuli provoke the activation of mesangial cells, fibroblasts, and EMT and lead to the production of a large amount of ECM components. There are many disputes regarding the possible origins of renal fibroblasts that include migrating hematopoietic or mesenchymal stem cells from the bone marrow, periadventitial cells, activation of resident interstitial fibroblasts, and EMT of tubular epithelial cells 24) . In addition to this cellular activation, the activation of signal molecules also results in the accumulation of matrix along the tubular basement membranes and within the interstitial area 15) . Transforming growth factor beta (TGF-β) is regarded as the key mediator of renal fibrosis in CKD 25) . TGF-β can be produced by both resident kidney cells and infiltrating leukocytes and 
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filtered from the plasma during proteinuria 15) . The 3 isoforms of TGF-β (TGF-β1, TGF-β2, and TGF-β3) are broadly expressed and act on almost every cell type in mammals by engaging in an intracellular signaling cascade of Smad family of proteins through ligand-induced activation of heteromeric transmembrane TGF-β receptor kinases 25) . In the UUO model, the downstream signaling of TGF-β1 is profoundly related to a family of Smad proteins that stimulate fibrosis (Smad2 and Smad3) or inhibit fibrosis (Smad7) 26) . TGF-β stimulates the myofibroblastic activation or transition of mesangial cells, interstitial fibroblasts, and tubular epithelial cells to become matrix-producing fibrogenic cells in vitro 1, 25) . Overexpression of TGF-β also causes glomerular and interstitial fibrosis in transgenic mice 27) . These fibrotic effects of TGF-β can be summarized by 2 cellular events, apoptosis and EMT. TGF-β-induced apoptosis usually results in podocyte depletion, glomerulosclerosis, loss of glomerular and peritubular capillaries, and tubular atrophy 28, 29) . On the other hand, TGF-β-induced EMT can play a critical role in tubular atrophy and generation of interstitial myofibroblasts 30) . On the basis of this experimental background, many therapeutic trials on renal fibrosis such as neutralizing anti-TGF-β antibody and TGF-β receptor inhibitor have been performed 31, 32) . However, no conclusive results could be obtained since mice with TGF-β deficiency die of massive inflammation; this is because TGF-β is one of the anti-inflammatory cytokines. In addition, the over-expression of TGF-β1 in transgenic mice has been reported to attenuate the development of renal fibrosis via an anti-inflammatory effect 33) . Therefore, to improve the clinical application of TGF-β for preventing renal fibrosis, additional information regarding more complicated mechanisms underlying TGF-β action should be revealed.
Angiotensin II (AngII) has also been known as one of the key mediators of inflammation and fibrosis in kidney diseases 34) . AngII signal transduction is initiated by 2 receptors, AngII type 1 (AT 1 ) and AngII type 2 (AT 2 ) receptors 35) . Most of the effects of AngII are mediated through the AT 1 receptor, which is widely expressed by most cell types, whereas the expression of the AT 2 receptor is higher in the fetal tissue and decreases in adult animals and humans [36] [37] [38] . Interestingly, the AT 2 receptor has been thought to counteract the effects of AngII and to play a role in the protection of the kidney 39) . AngII through AT 1 receptor regulates ECM accumulation mediated by profibrotic growth factors such as TGF-β 34) . Clinically, in humans with chronic renal allograft rejection, plasma TGF-β levels were found to decrease after AngII was blocked 40) . AngII also stimulates oxidative stress, which in turn upregulates the vasoconstrictor peptides due to increased catabolism of nitric oxide (NO) 41) . Because NO plays an essential role in the regulation of blood flow in the normal and diseased kidneys, the changes of blood flow in UUO are associated with the impairment of the NO synthetic pathway in the kidney 42) . However, because angiotensin itself has a very important role in the development and maturation of a normal kidney, an angiotensin-converting enzyme (ACE) inhibitor can aggravate renal interstitial inflammation and fibrosis in a neonatal rat model with partial UUO 43) . Connective tissue growth factor (CTGF) is an important profibrotic factor that contributes to renal fibrosis and tubuloepithelial transdifferentiation as a downstream mediator of TGF-β activity 44) . Interstitial production of CTGF was found to increase in areas of chronic renal injury in humans 45) and to be attenuated by ACE inhibitors and antagonists of AT 1 receptor 46, 47) . Lin et alreported that pentoxifylline suppresses the activity of CTGF in rats with UUO by interfering with Smad3-and Smad4-dependent CTGF transcription 48) . Platelet-derived growth factor (PDGF) is also centrally involved in the pathogenesis of renal fibrosis, similar to CTGF 3, 49) . In a rat model with progressive mesangioproliferative glomerulonephritis, the treatment with an antagonist against PDGF-B attenuated mesangioproliferative changes, glomerular hypertrophy, and podocyte damage, and in the long term prevented glomerulosclerosis and tubulointerstitial damage 49) . Of the PDGF family, PDGF-C and D are also increased in the area of tubulointerstitial fibrotic lesion, suggesting a potential role in renal fibrosis 50, 51) . Endothelin-1 (ET-1) that is abundant in renal endothelial cells is a strong vasoconstrictor peptide with profibrotic and pro-inflammatory effects 52) . Glomerular ET-1 expression was remarkably elevated in streptozotocin-induced diabetic rats 53) . Overexpression of ET-1 is sufficient to induce structural and functional changes, including glomerular and tubulointerstitial fibrosis, because ET-1 causes hypoxic injury due to the constriction of peritubular capillaries and stimulates mesangial cell proliferation and ECM production 54, 55) . Kon et al. 56) suggested that antagonism of ET-1 may attenuate tubulointerstitial injury in an experimental model of chronic cyclosporine nephrotoxicity. In addition, tumor necrosis factor alpha (TNF-α) and interleukin-1 (IL-1) are other candidate proinflammatory cytokines that can lead to renal fibrosis 57, 58) . Simultaneously, other antifibrotic factors may be involved in the pathway of renal fibrosis combined with profibrotic cytokines and growth factors.
Hepatocyte growth factor (HGF), a promoter of hepatocyte proliferation and liver generation, is also regarded as an antifibrotic mediator of tubular repair and generation after acute renal injury 59, 60) . Moreover, HGF prevents the initiation and progression of chronic renal fibrosis and attenuates TGF-β1 expression in various animal models 60) . In a mice model with UUO, the administration of exogenous HGF noticeably reduced the progression of renal fibrosis and attenuated the expression of α-smooth muscle actin, TGF-β 61) . In addition, in an animal model of diabetic nephropathy, HGF interrupted the progression of renal fibrosis and dysfunction 62) . These antifibrotic results of HGF can be explained by various antagonistic effects on the cellular activation of renal fibrosis. HGF blocks tubular EMT 63) , inhibits apoptosis of endothelial cells 64) , and accelerates matrix degradation by modulating both the plasminogen activator/plasmin and matrix metalloproteinases (MMPs) proteolytic pathway 65) . Bone morphogenetic protein-7 (BMP-7), formerly known as osteogenic protein-1, is a member of the TGF-β superfamily and a key growth factor of embryogenesis and morphogenesis 66) . Recently, BMP-7 has been reported to reverse renal fibrosis induced by TGF-β in a mice model and to antagonize TGF-β-dependent fibrogenesis in mesangial cells 67, 68) . In addition, interferon gamma (IFN-γ) and insulin-like growth factor-1 (IGF-1) are also known to have an antifibrotic effect 57, 69) . There is always a balance between matrix production and degradation in the normal renal tissue, whereas the excessive accumulation and deposition of ECM components are the final pathologic results in renal fibrosis and CKD. Fibrotic appearance in renal fibrosis may be induced by both overproduction of matrix components and defects in their degradation 1) . The normal kidney usually produces various proteases, including MMP, plasminogen activator, and lysosomal cathepsins 70) . The balance between matrix production and degradation can be maintained through appropriate degradation of ECM due to the potent proteases. Therefore, these proteases have been regarded as one of the possible candidates for the treatment of renal fibrosis 70) . However, recent data suggest that the action mechanisms of proteases are not simple. In an animal model, ironically, deficiency of plasminogen attenuates renal fibrosis, and overproduction of MMP produces spontaneous EMT and peritubular fibrosis in renal proximal tubules 71, 72) . Fig. 2 summarizes the cellular and molecular activation of renal fibrosis (Fig. 2) .
Although we have secured various possible targets for the treatment of renal fibrosis as mentioned above, it is evident that there is no effective treatment for renal fibrosis thus far. Boor et al. 73) reported several problems that even we faced, including discrepancy between rodent models and clinical situation, lack of multiple models, different parameters and techniques for the evaluation of fibrosis, and inadequate timing of treatment in the experimental fibrosis.
Conclusion
Although renal fibrosis, including tubulointerstitial fibrosis and glomerulosclerosis, is always the final common outcome in CKD, the pathogenic mechanisms underlying renal fibrosis are extremely complicated. Both cellular activation such as EMT; fibroblast activation; monocyte/macrophage infiltration; cellular apoptosis, and the activation of profibrotic cytokines such as TGF-β, AngII, CTGF, PDGF, ET-1, TNF-α, and IL-1 result in the excessive accumulation of ECM. Antifibrotic cytokines such as HGF, BMP-7, IFN-γ, and IGF-1 or several proteases such as MMP and plasminogen activator may be possible candidates for the treatment of renal fibrosis; however, our knowledge about these candidates is still limited. Further studies are needed to elucidate the complicated pathogenesis of renal fibrosis and to overcome the irreversibility of CKD. Eddy SS 15) . Abbreviations: EMT: epithelial-tomesenchymal transition, TGF-β: transforming growth factor beta, AngII: angiotensin II, CTGF: connective tissue growth factor, PDGF: platelet-derived growth factor, ET-1: endothelin-1, TNF-α: tumor necrosis factor alpha, IL-1: interleukin 1, ECM: extracellular matrix, HGF: hepatocyte growth factor, BMP-7: bone morphogenetic protein 7, IFN-γ : interferon gamma, IGF-1: insulin-like growth factor 1, and MMP: matrix metalloproteinases.
